|Bid||5.52 x 800|
|Ask||9.10 x 1100|
|Day's Range||8.46 - 8.67|
|52 Week Range||6.66 - 16.37|
|Beta (5Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.
Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal, not only for Alzheimer's patients, but for Biogen and its shareholders. There are two other biotech stocks, however, whose recent breakthroughs could drive the profits for years to come, and they are still priced modestly -- for now.